Not all individuals with CLL demand therapy. In spite of all recent improvements, the iwCLL even now suggests watchful observation for patients with asymptomatic disease.86 This recommendation relies on no less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 The two trials https://georgeu344czr6.is-blog.com/profile